Chronic Lymphocytic Leukemia

The most common adult leukemia in Western countries — CD5+ B-cell clone, IGHV mutation status, del(17p)/TP53, and the BTK inhibitor and venetoclax revolution

Key Points

• CLL is the most common adult leukemia in Western countries (~18,740 new cases projected in the US in 2024), arising from clonal CD5+/CD19+/CD23+ B cells with a characteristic indolent but incurable course.
• IGHV mutation status is the most important prognostic biomarker: unmutated IGHV (≤2% from germline) confers shorter time-to-treatment and overall survival; mutated IGHV has a more indolent course and retains benefit from FCR chemoimmunotherapy.
• High-risk cytogenetics drive treatment selection: del(17p)/TP53 mutation (~7–10%) confers resistance to chemoimmunotherapy; del(11q) predicts aggressive disease; del(13q) as sole abnormality is favorable; trisomy 12 is intermediate.
• BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are now preferred first-line therapy for most patients, providing indefinite progression-free survival with oral continuous dosing.
• Venetoclax + obinutuzumab (CLL14 trial, fixed 12-month duration) is a highly effective time-limited alternative for unfit patients; venetoclax + ibrutinib (GLOW/CAPTIVATE trials) for fit patients.
• FCR (fludarabine + cyclophosphamide + rituximab) remains a viable option for young fit patients with mutated IGHV, achieving durable remissions (~40% remain progression-free at 10+ years).
• Richter's transformation — clonal evolution to DLBCL (~5–10%) or Hodgkin lymphoma (~1%) — carries a very poor prognosis (median OS ~8–12 months) and requires urgent re-biopsy when suspected.

Epidemiology & Pathobiology

Chronic lymphocytic leukemia is the most prevalent leukemia in Western countries, with approximately 18,740 new cases and 4,490 deaths projected in the United States for 2024. The median age at diagnosis is 70 years; CLL is exceedingly rare before age 40 and accounts for ~25–30% of all leukemias in the US. CLL is nearly twice as common in men as in women and is significantly more common in White Americans than in Asian or Black populations — a striking demographic contrast to other hematologic malignancies. CLL and small lymphocytic lymphoma (SLL) are the same disease: CLL is defined by…

Prognostic Biomarkers & Genetic Features

CLL is defined by a complex prognostic landscape that has been transformed by molecular testing: IGHV mutation status (the most important single prognostic factor): • Mutated IGHV (M-CLL, ≥2% deviation from germline): Indolent disease; median OS >10–25 years; retains benefit from FCR chemoimmunotherapy (10-year PFS ~40% in some series); derives somewhat less robust benefit from BTK inhibitors than unmutated IGHV. • Unmutated IGHV (U-CLL, <2% deviation): More aggressive; shorter time-to-first-treatment and OS; strongly benefits from BTK inhibitors; FCR does not produce durable remissions.…

Clinical Presentation & Staging

CLL most commonly presents as an incidental finding on routine complete blood count — the majority of patients are asymptomatic at diagnosis. The classic laboratory finding is an isolated, persistent lymphocytosis of mature-appearing small lymphocytes. Common presenting findings: • Incidental lymphocytosis: Most common presentation; found on routine CBC or pre-operative workup • Lymphadenopathy: Painless, rubbery, symmetrical peripheral lymphadenopathy — cervical, axillary, and inguinal; firm but non-tender • Splenomegaly and/or hepatomegaly: Spleen can become massively enlarged; causes left…

Treatment: Indications & First-Line Options

Watch-and-wait is the standard approach for early-stage, asymptomatic CLL (Rai 0–II, Binet A–B without symptoms). Multiple randomized trials have demonstrated no benefit from early treatment of asymptomatic CLL — treatment is initiated when the disease becomes active (IWCLL criteria for treatment): Indications for treatment initiation (IWCLL 2018 — any one): • Symptomatic progressive marrow failure (anemia Hgb 6 cm below costal margin) or progressive splenomegaly • Massive (>10 cm) or progressive lymphadenopathy • Progressive lymphocytosis (>50% increase over 2 months or lymphocyte doubling…

Relapsed/Refractory CLL & Special Situations

Relapsed/refractory CLL therapy: • If BTK inhibitor-naive at relapse: BTK inhibitor ± anti-CD20 antibody; venetoclax + rituximab (MURANO trial: 2-year fixed duration; superior PFS vs. BR at 5 years — PFS 54% vs. 5%). • BTK inhibitor-refractory: Venetoclax-based therapy (MURANO regimen); pirtobrutinib (non-covalent BTK inhibitor, FDA approved 2023 — BRUIN trial: ORR 73% after prior covalent BTK inhibitor; active against C481S mutation). • Venetoclax-refractory: BTK inhibitor if not prior; pirtobrutinib; lisocabtagene maraleucel (CAR-T, FDA approved 2024 for R/R CLL after ≥2 prior lines…